Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 8/20 | 0.39 |
| ▸ | CA2 | P00918 | 8/20 | 0.39 |
| ▸ | CA12 | O43570 | 7/20 | 0.39 |
| ▸ | CA9 | Q16790 | 7/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PKLR | P30613 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26613454 | 0.84 | ESR1 (0.50) | ESR1ESR2PTGS2PTGS1CA1 | |
| SCHEMBL26613392 | 0.81 | ESR1 (0.50) | ESR1ESR2PTGS2PTGS1CA1 | |
| SCHEMBL26613388 | 0.81 | ESR1 (0.53) | ESR1ESR2PTGS2PTGS1CA1 | |
| SCHEMBL29746449 | 0.81 | ESR1 (0.51) | ESR1ESR2KIF11PARP1PARP2 | |
| SCHEMBL15888360 | 0.81 | ESR1 (0.51) | ESR1ESR2KIF11PARP1PARP2 | |
| SCHEMBL26613441 | 0.81 | ESR1 (0.51) | ESR1ESR2KIF11PARP1PARP2 | |
| SCHEMBL29746019 | 0.78 | ESR1 (0.44) | ESR1ESR2PTGS2PTGS1CA1 | |
| SCHEMBL26613384 | 0.78 | ESR1 (0.44) | ESR1ESR2PTGS2PTGS1CA1 | |
| SCHEMBL29746029 | 0.78 | PTGS2 (0.43) | ESR1ESR2PTGS2PTGS1CA1 | |
| SCHEMBL26613422 | 0.78 | PTGS2 (0.43) | ESR1ESR2PTGS2PTGS1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083723-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | TORAY INDUSTRIES, INC. (JP) | 2026-03-26 | — | — | US | disclosed |
| US-12570639-B2 | Tetrahydroquinoline derivative and medicinal use thereof | TORAY INDUSTRIES, INC. (JP) | 2026-03-10 | — | — | US | disclosed |
| EP-4545079-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | Toray Industries, Inc. (JP) | 2025-04-30 | — | — | EP | disclosed |
| CN-119403554-A | Therapeutic or prophylactic agent for amyotrophic lateral sclerosis | 东丽株式会社 | 2025-02-07 | — | — | CN | disclosed |
| US-20240116903-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2024-04-11 | — | — | US | disclosed |
| WO-2023249105-A1 | THERAPEUTIC AGENT OR PREVENTIVE AGENT FOR DRUG-INDUCED MYOCARDIAL DISORDERS | 東レ株式会社 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249106-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | 東レ株式会社 | 2023-12-28 | — | — | WO | disclosed |
| WO-2023249107-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR PERIPHERAL NERVE DISORDER | 東レ株式会社 | 2023-12-28 | — | — | WO | disclosed |
| EP-4269392-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | Toray Industries, Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| EP-4269392-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | Toray Industries, Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| CN-116648245-A | Tetrahydroquinoline derivative and medical application thereof | 东丽株式会社 | 2023-08-25 | — | — | CN | disclosed |
| WO-2022138888-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | 東レ株式会社 | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116903-A1 | TETRAHYDROQUINOLINE DERIVATIVE AND MEDICINAL USE THEREOF | AIFM2, TXNRD2, NFE2L2 | ESR1 3731/4885ESR2 1215/4885KIF11 4421/4885 |
| US-20260083723-A1 | THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS | AIFM2, GPX1, SOD1 | ESR1 3396/4885ESR2 860/4885KIF11 4642/4885 |
| US-12570639-B2 | Tetrahydroquinoline derivative and medicinal use thereof | AIFM2, GPX1, GPX4 | ESR1 3178/4885ESR2 411/4885KIF11 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.